Use code NEW15 and save 15% Sitewide.
Cookies
We use cookies for analytics to understand how the site is used and to improve it. See our privacy policy.
39-amino-acid dual-receptor agonist (GIP and GLP-1) — studied in incretin pharmacology research.
Select size
Quantity
Ships within 1 business day
Tirzepatide is a 39-amino-acid synthetic peptide that hits two different metabolic receptors at once: GIP and GLP-1, both members of the "incretin" family. A C20 fatty-acid tag at one specific amino acid (Lys-20) helps it stick to albumin in lab conditions, extending its useful research half-life. It's the dual-agonist counterpart to Retatrutide's triple-agonist activity.
How it's been studied: Cell-culture work has compared Tirzepatide's potency at GIP vs. GLP-1 receptors against single-agonist peptides, and pancreatic-β-cell-line studies have examined how the combined receptor activity shapes insulin-release signaling. Although clinical research exists, this product is research-use-only.
Where you'll see it in research:
Handling notes: Fatty-acid tag extends half-life via albumin binding. Standard peptide handling.
Every batch is third-party tested for purity, identity, and contaminants. Download the COA for the lot you receive.
Molecular Weight
4813.45 g/mol
Form
Lyophilized powder
Storage
Lyophilized: 2-8°C up to 24 months. Reconstituted: 2-8°C, use within 30 days.
Sequence
39-AA dual GIP/GLP-1 agonist with γ-Glu-C20 fatty-acid modification at Lys-20
All compounds are sold individually and do not include reconstitution supplies, syringes, or aliquoting tools. Products ship in lyophilized (freeze-dried) form and require proper reconstitution before use in research settings. See our Reconstitution Solution page for laboratory-grade bacteriostatic water.
Research use only — not for human or animal consumption. See our Research Use Disclaimer.